checkAd
    Startseite > Aktien > Hutchmed (China) > Nachrichten
    Hutchmed (China) Aktie
    3,4200
     
    EUR
    -3,93 %
    -0,1400 EUR
    Letzter Kurs 26.04.24 Tradegate
    3,3200
     
    EUR
    453 STK
    Geldkurs 26.04.24
    3,5000
     
    EUR
    428 STK
    Briefkurs 26.04.24
    ISIN: KYG4672N1198 · WKN: A2PJ5B · SYM: H7T2 · Kaiman-Inseln

    Neueste Nachrichten

    HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
    26.04.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Highlights Data to be Presented at AACR Congress 2024
    05.04.24 · globenewswire · Hutchison China Meditech
    HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
    02.04.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
    28.03.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
    22.03.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
    28.02.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
    07.02.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
    02.02.24 · globenewswire · Hutchison China Meditech
    HUTCHMED to Announce 2023 Final Results
    01.02.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
    30.01.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
    11.01.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
    09.11.23 · globenewswire · Hutchison China Meditech